Fig 1: Overexpression and knockdown of RASAL2 expression in ACHN cells. (A) RASAL2 expression was evaluated in ACHN cells using reverse transcription-quantitative PCR, (B) western blotting and (C) immunofluorescence staining following transfection with plasmids expressing either the RASAL2 protein or shRASAL2. Magnification, x200. *P<0.05 vs. Control group. #P<0.05 vs. scramble group. Blank, un-transfected control; Control, control pcDNA.31 plasmid; sh, short hairpin RNA; scramble, scrambled shRNA; RASAL2, ras protein activator like 2; shRASAL2, RASAL2 shRNA.
Fig 2: Effect of manipulating RASAL2 expression on MMP-2, MMP-9 and TIMP-1 expression in RCC cells. Protein expression of MMP-2, MMP-9 and TIMP-1 was assessed by western blotting in ACHN cells following RASAL2 overexpression or knockdown. GAPDH was used as the loading control. *P<0.05 vs. Control group. #P<0.05 vs. scramble group. Blank, un-transfected control; Control, control pcDNA.31 plasmid; sh, short hairpin RNA; scramble, scrambled shRNA; RASAL2, ras protein activator like 2; shRASAL2, RASAL2 shRNA; MMP, matrix metalloproteinase; TIMP-1, tissue inhibitor of metalloproteinases 1.
Fig 3: Suppressed RASAL2 and Bcl-2 expression and upregulated Bax expression in A549 cells following transfection with miR-654-3p mimics. The mRNA and protein expression levels were analyzed by RT-qPCR and western blotting following transfection with miR-654-3p mimics for 48 h. Expression of (A) RASAL2, (B) Bcl-2 and (C) Bax following transfection with mimics. (D) Protein expression levels of RASAL2, Bcl-2 and Bax. (E) Statistical data were presented. **P<0.01 vs. the control groups. Bcl-2, B cell lymphoma-2; Bax, Bcl-2-associated X protein; Control, untreated group; NC, negative control group; miR, microRNA; Mimics, cells transfected with miR-654-3p; RASAL2, ras protein activator like 2.
Fig 4: Downregulated miR-654-3p expression and upregulated RASAL2 expression in lung cancer tissues. The expression of miR-65-3p and RASAL2 was determined by reverse transcription-quantitative polymerase chain reaction and western blotting. (A) Expression of miR-654-3p in tumor tissues. (B) Expression of RASAL2 in tumor tissues. (C) Negative correlation was observed between the expression of miR-654-3p and RASAL2. (D) Protein expression levels of RASAL2. (E) Quantitative analysis of D. **P<0.01. miR, microRNA; RASAL2, ras protein activator like 2.
Fig 5: RASAL2 expression was decreased in RCC tissues. (A) Comparison of RASAL2 mRNA expression in normal and RCC tissues, measured using reverse transcription-quantitative PCR. (B) Comparison of RASAL2 protein expression in normal tissue and RCC tissues, measured using western blotting. (C) Comparison of RASAL2 protein localization in normal and RCC tissues, as measured using immunohistochemical staining. Scale bars=100 µm (upper panel); Scale bars=50 µm (lower panel). *P<0.05 vs. normal RCC tissue. @P<0.05 vs. low-grade RCC. #P<0.05 vs. middle-grade RCC. RCC, renal cell carcinoma; RASAL1, ras protein activator like 2.
Supplier Page from Abcam for Anti-RASAL2 antibody